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Background/aim: Coronavirus disease 2019 (COVID-19) shares some clinical features with new-onset granulomatosis with
polyangiitis (GPA) or GPA flare that may lead to a challenge in differential diagnosis. To date, little is known whether GPA can be
induced by COVID-19. Herein, we aimed to seek the frequency and mortality rates of COVID-19 in our GPA cohort, and along with the
literature cases, to evaluate clinical features and treatments of GPA patients with COVID-19. We also tried to identify clinical features
of COVID-19 induced GPA.
Materials and methods: As of July 2021, we conducted a systematic literature review using different spelling combinations of
“COVID-19 and GPA” in the PUBMED database. In total, 18 cases were found in the literature, 6 of them had COVID-19 induced GPA.
The remaining 12 of literature cases and 6 cases in our GPA cohort (n = 81) had a COVID-19 infection while followed-up with GPA. We
grouped these 18 patients as GPA+COVID-19.
Results: The frequency of COVID-19 was 7.4% in GPA cohort and mortality rate was 33% in GPA patients with COVID-19. The most
common symptoms of GPA+COVID-19 patients were fever, cough, arthralgia/myalgia, and malaise. The most frequent treatments
for GPA before the COVID-19 infection were steroids (72%) and rituximab (56%). Three patients who received rituximab also had
COVID-19 reinfection. In the literature cases, mortality was observed in 4 (22%) of 18 patients with GPA+COVID-19. The most
common symptoms of COVID-19 induced GPA were dyspnea, fever and cough.
Conclusion: In our GPA cohort, we observed a higher mortality rate compared to global WHO data. In patients followed up with GPA,
rituximab treatment may be precarious for both COVID-19 disease and reinfection. Our study also provided some clues about the
diagnostic challenge of GPA induced by COVID-19.
Key words: Coronavirus disease 2019, severe acute respiratory syndrome coronavirus 2, granulomatosis with polyangiitis, Wegener’s
granulomatosis, rituximab

1. Introduction
Coronavirus disease 2019 (COVID-19), which is caused
by severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2), could be mostly mild, but some patients
could develop severe disease with pneumonia, acute
respiratory failure and sepsis which may lead to mortality.
In COVID-19, approximately 80% of cases are mild, 15%
severe and 5% critical [1, 2]. Advanced age, male sex, and
comorbidities such as obesity, diabetes mellitus, cardiac
and pulmonary diseases are the poor prognostic factors
for COVID-19 [3]. SARS-CoV-2 induces viral pyroptosis
(severe inflammatory programmed cell death) in infected

respiratory epithelial cells, like other cytopathic viruses.
That cell/tissue destruction may trigger a subsequent
inflammatory response In fact, in most patients, the
immune system suffices to eliminate or limit this process.
However, in some patients inflammation, because of a
dysfunctional immune response1, could not be limited and
a cytokine storm is triggered [4].
Granulomatosis with polyangiitis (GPA) is a systemic,
necrotizing vasculitis mediated by antineutrophil
cytoplasmic antibodies (ANCA) against proteinase 3
(PR3). The respiratory manifestations of GPA may be
mild, similar to many viral respiratory tract infections

SSRN (2020). Cell Pyroptosis, a Potential Pathogenic Mechanism of 2019-nCoV Infection [Online]. Website https://ssrn.com/abstract=3527420 [accessed 01 July 2021].
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with malaise, arthralgia and respiratory tract symptoms,
or it may be characterized by more severe lower respiratory
tract symptoms and even acute respiratory failure because
of alveolar hemorrhage and may cause mortality [6–9].
In the literature, the variable clinical course of
COVID-19 is also reported in patients with autoimmune
rheumatic diseases (ARD). Ultimately, there are not
enough studies with a high level of evidence to enable us
to evaluate the course of SARS-CoV-2 infection, especially
in the rare ARDs like vasculitides [9–13]. According to
various case series, active rheumatological disease, organ
involvement, and some immunosuppressive therapies such
as rituximab and glucocorticoid (especially prednisolone
>10 mg/day or equivalent dose) could lead to a worse
course of COVID-19 disease. On the other hand, the
effects of other antirheumatic drugs on COVID-19 course
are not clear. Even, the inflammatory processes associated
with SARS-CoV-2 infection could be restricted to some
immunosuppressive agents by the effect of suppressing
proinflammatory cytokine pathways [14–16]. Antibodyassociated immunity is one issue recently examined
in COVID-19. Although the effect of B-cell-depleting
rituximab on viral clearance is not yet clear. These agents
might alter COVID-19 elimination rates, disease course
or prognosis [17, 18]. Since various immunosuppressives,
including B-cell depleting agents, are used in GPA, it is
important to evaluate the course of COVID-19 in this
patient group. Additionally, the differential diagnosis of
all ANCA-related vasculitis (AAV) from the COVID-19
is challenged due to similar clinical, laboratory, and
radiological features. To date, GPA has only been presented
as COVID-19 induced or coinfection in few case reports
[10, 19, 20].
Therefore, we aimed to evaluate the clinical course,
mortality of COVID-19 in our GPA patients with cases
compiled in the literature.
2. Material and method
As of July 2021, we conducted a systematic literature
review using a combination of the terms “COVID-19” or
“Covid-19” or “covid-19” or “COVID 19” or “Covid 19”
or “covid 19” with “Granulomatosis with polyangiitis”
or “Wegener’s granulomatosis” or “ANCA associated
vasculitis” or “GPA” in the PUBMED database. In the
included publications, language was limited to “English”.
While preparing this article, the articles on patients with
GPA who had COVID-19 infection or who were diagnosed
COVID-19 infection induced GPA, together with the
different definitions above, were taken into consideration.
The literature review was carried out by MAE, SCG
and all authors worked in collaboration in selecting and
obtaining the data. The study protocol was approved by
the local ethics committee (E2-21-173). In the selection
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process, first the title and abstract of the articles were
evaluated. In this evaluation, 54 articles were found
that could be related to our subject (Figure). In total,
19 of these articles were about patients with GPA who
had COVID-19 or GPA induced by COVID-19. All
GPA patients were meeting the American College of
Rheumatology diagnostic criteria [21]. After all, 18 case
reports including 18 patients’ full texts of which could be
accessed, were evaluated within the scope of our study. A
total of 12 GPA cases who had COVID-19 were presented
as case report in the literature to date [6, 22–32]. The
remaining 6 cases were diagnosed with GPA following
COVID-19 and presented as COVID-19 induced in the
literature [19, 20, 33–36]. Thus, we also grouped these
patients as COVID-19 induced GPA patients. Besides
12 cases from the literature [6, 22–32], COVID-19 was
detected in 6 patients in our GPA cohort. These18 patients
were grouped as GPA+COVID-19. In total, 24 patients (18
GPA+COVID-19 and 6 COVID-19 induced GPA) were
included in this study.
Demographics, clinical characteristics, comorbidities,
organ involvements and treatments of GPA and ANCA
serology of our patients were evaluated with the cases
in the literature. Enzyme-linked immunosorbent assay
(ELISA) and immunofluorescent antibody assay (IFA)
methods were used to detect perinuclear (p-ANCA)
or cytoplasmic (c-ANCA) ANCA staining and for
proteinase 3 (PR3-ANCA) or myeloperoxidase (MPOANCA) antibody positivity, respectively. Besides these
data, clinical features, organ involvements of COVID-19,
hospitalization, length of hospitalization, requirement
for systemic glucocorticoids or oxygen support and
mortality due to COVID-19 were also recorded. All
systemic glucocorticoid doses, including prednisolone
and deflazacort used by the patients, were recorded as
methylprednisolone equivalent. Birmingham Vasculitis
Activity Score (BVAS) before COVID-19 infection and
Vasculitis Damage Index (VDI) and Revised Five Factor
Score (FFS) scores after COVID-19 infection were also
evaluated [37–39]. Pre- and post-COVID-19 BVAS scores
were calculated using the prescribed scoring algorithm and
grouped as remission, persistent and new/worse [39, 40].
COVID-19 diagnosed in our GPA cohort by positive nasal
swab reverse transcriptase–polymerase chain reaction
(RT-PCR) or compatible thorax computed tomography
(CT) findings accompanied by clinical symptoms of
COVID-19. We searched all our GPA patients’ medical
records in the hospital database and contacted them via
telephone.
Statistical analysis was performed using the Statistical
Package for the Social Sciences version 22 (SPSS v.22).
The variables were investigated using visual (histograms,
probability plots) and analytical methods (Shapiro–
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Wilk’s test) to determine whether or not they are
normally distributed. Descriptive analyses were presented
using tables of frequencies for the ordinal variables
and using medians and interquartile range (IQR) or
minimum-maximum (min-max) for the nonnormally
distributed mean and standard deviation, as indicated.
Categorical variables are presented as percentages. The
Mann–Whitney U test or Student’s t-test were used
for comparison of continuous variables, according to
normality of distribution. For the evaluation of categorical
variables, the Pearson’s chi-squared test and Fisher’s exact
test were used, as indicated. The Wilcoxon test was used to
compare the change in BVAS score between pre- and postCOVID-19 disease. For all comparisons, p values <0.05
were considered statistically significant.
3. Results
3.1 COVID-19 and GPA outcomes
COVID-19 was seen in 6 (7.4%) of the 81 GPA patients
under follow-up in our cohort. A total of 18 patients
(12 GPA patients from the literature and 6 from our
cohort) were grouped as GPA+COVID-19. The median
(min-max) age of 18 GPA+COVID-19 patients was 55.6
(21–88) years. Demographic, clinical and laboratory
characteristics of GPA+COVID-19 patients were shown in
Table 1. The most common comorbidity was hypertension
(n = 7, 39%). The most common symptom of COVID-19
was fever (67%) and at least half of the patients had cough,
fatigue and arthralgia/myalgia. Eleven patients (61%) had
both RT-PCR positivity and an appearance compatible
with COVID-19 on thorax CT, and 5 (29%) patients had
only RT-PCR positivity (thorax CT of 3 patients was not
compatible with COVID-19 and 2 patients did not have
any data about pulmonary imaging). In 2 (12%) patients
with a history of contact with a SARS-CoV-2 positive
individual, COVID-19 diagnosed based on typical
pulmonary radiological and clinical findings. At the time
of COVID-19 diagnosis, 14 patients (78%) were using
glucocorticoids due to GPA, of which 8 were using lowdose, 3 medium-dose and 2 high-dose. Glucocorticoid
dose in one of the literature cases had not been reported.
Patients were compared according to prednisone use
prior to COVID-19 infection. There was no difference in
terms of oxygen requirement, hospitalization length, ICU
admission, and mortality between patients who received
any dose of prednisone and those who did not. In total, 10
patients (59%) received rituximab and 9 patients received
cyclophosphamide therapy due to GPA. Two of them
were under active cyclophosphamide induction regimen
for GPA at the time of COVID-19 diagnosis. There were
8 patients who received rituximab therapy in the last
12 months before COVID-19 diagnosis, while the time
between the last rituximab infusion and the development

of COVID-19 was unknown in 2 patients. Apart from
these, azathioprine was administered to 4 patients (24%),
methotrexate to 2 (12%), and mycophenolate mofetil to 1
(6%). During COVID-19, it was determined that 7 (39%)
of 18 patients needed oxygen support.
Comparison of our and literature cases in terms of
BVAS scores before and after COVID-19 was shown in
Table 2 and VDI and revised FFS scores before COVID-19
infection was shown in Table 3. The median (min-max)
BVAS score was 1 (0–11) before COVID-19, and 1 (0–6)
after COVID-19 (p = 0.273). Detailed clinical features of
all GPA patients with COVID-19 disease were presented
in Table 4.
3.2 GPA and COVID-19 reinfection
Among GPA+COVID-19 patients, COVID-19 reinfection
was reported in 3 patients (2 females and 1 male). These
were cases in the literature and were receiving rituximab.
Besides rituximab treatment, one of these patients was
taking prednisone (30 mg/day) plus cyclophosphamide,
and the other was taking only prednisone 5 mg/day. Oxygen
support was needed in 2 patients, but no mortality was
observed in these 3 patients. All patients had stable disease
BVAS scores before and after COVID-19 reinfection. The
time interval between two courses of COVID-19 was as
follows for the 3 cases: after 43 days with 2 negative PCR
control, 47 days with 1 negative PCR control and after six
months with 3 negative PCR control and seroconversion.
3.3 COVID-19 related mortality in GPA patients
In our GPA cohort, COVID-19 mortality was 33% (n =
2/6). Along with literature cases, mortality was observed
in 4 (22%) of 18 GPA+COVID-19 patients (Table 1).
Comparison of deceased and surviving GPA+COVID-19
patients was similar in terms of age, sex, pulmonary and
renal involvement due to GPA, median steroid dose,
rituximab usage, and pulmonary involvement in thoracic
CT due to COVID-19 (Table 5). Of the patients who died,
2 were receiving rituximab (1 patient from our cohort)
and 2 glucocorticoid alone. Although all deceased patients
had a higher median (min-max) revised FFS and VDI
score before COVID-19 disease, there was no statistically
significant difference [2 (2–2) vs. 1 (0–2), p = 0.073 and
2 (0–6) vs. 0 (0–6), p = 0.310, respectively]. The median
BVAS values of all patients before COVID-19 disease were
0 (0–3), while it was 1 (0–11) in survivors (p = 0.611).
3.4. COVID-19 induced GPA
There were 6 cases diagnosed with GPA after COVID-19
infection, all of which were reported in the literature.
Demographic and clinical characteristics of these patients
were shown in Table 6. The time interval between
COVID-19 and diagnosis of GPA ranged from 10 days
to 1 month for all 6 cases. Of these patients, c-ANCA
positivity was found in 5 and PR-3 ANCA in 1, and also
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Table 1. Comparison of demographic, clinical and laboratory characteristics of GPA+COVID-19 cases between literature and our cases.
GPA+COVID-19 cases
Literature cases (n = 12)

Our cases (n = 6)

Total (n = 18)

Median age, years (min-max)

53.5 (21–80)

62.5 (43–88)

57.0 (21–88)

Male, n (%)

7 (58)

4 (67)

11 (61)

Female, n (%)

5 (42)

2 (33)

7 (39)

Hypertension

3 (25)

4 (67)

7 (39)

Chronic kidney disease

2 (17)

2 (33)

4 (22)

Hyperlipidemia

2 (17)

2 (33)

4 (22)

Obesity

1 (8)

1 (17)

2 (11)

Coronary artery disease

0

1 (11)

1 (6)

Diabetes mellitus

1 (8)

0

1 (6)

Osteoporosis

1 (8)

0

1 (6)

Fever

8 (67)

4 (67)

12 (67)

Cough

9 (75)

1 (17)

10 (56)

Fatigue

4 (33)

5 (83)

9 (50)

Arthralgia/Myalgia

4 (33)

5 (83)

9 (50)

Dyspnea

4 (33)

3 (50)

7 (39)

Anorexia

1 (8)

4 (67)

5 (28)

Sore throat

2 (17)

1 (17)

3 (17)

Nausea

0

3 (50)

3 (17)

Vomiting

0

2 (33)

2 (11)

Ageusia

2 (17)

0

2 (11)

Rhinitis

1 (8)

1 (7)

2 (11)

Headache

1 (8)

1 (17)

2 (11)

Diarrhea

1 (8)

1 (17)

2 (11)

Hemoptysis

2 (17)

0

2 (11)

Fever with chills

1 (8)

1 (17)

2 (11)

Sputum

1 (8)

0

1 (6)

Anosmia

1 (8)

0

1 (6)

RT-PCR positivity, n (%)

12 (100)

4 (67)

16 (89)

Lymphopenia, n (%)

4 (33)

6 (100)

10 (56)

Ground glass opacitiesin thorax CT, n (%)

9 (75)

4 (67)

13 (72)

C-Reactive protein (>5 mg/L), n (%)

7 (58)

4 (67)

11 (61)

Need for O2 support, n (%)

4 (33)

3 (50)

7 (39)

Prednisone

10 (83)

4 (67)

14 (78)

Rituximab

9 (75)

1 (17)

10 (56)

Cyclophosphamide

1 (8)

1 (17)

2 (11)

Mycophenolate mofetil

1 (8)

0

1 (6)

Mortality, n (%)

2 (17)

2 (33)

4 (22)

Comorbidity, n (%)

COVID-19 symptoms, n (%)

Immunosuppressive usage for GPA, n (%)

RT-PCR: Reverse transcriptase–polymerase chain reaction, CT: Computed tomography, GPA: Granulomatosis with polyangiitis.
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Figure. Flow chart of article selection process
Table 2. Comparison of the pre-COVID-19 and post-COVID-19 Birmingham Vasculitis Activity Scores of our and literature
GPA+COVID-19 cases.
Our cases*

Literature cases**

Total

BVAS

Pre-COVID-19 Post-COVID-19 Pre-COVID-19 Post-COVID-19 Pre-COVID-19 Post-COVID-19

Remission

40

25

45

33

44

31

Persistent symptoms

40

75

37

45

37

54

0

18

22

19

15

New/worse symptoms 20

BVAS: Birmingham Vasculitis Activity Scores.
*The BVAS score of pre-COVID-19 in 1 and post-COVID-19 in 2 (due to mortality) were not available in our cases.
**
The BVAS score of pre-COVID-19 in 1 and post-COVID-19 in 3 (2 of them due to mortality) were not available in the literature cases.

Table 3. Comparison of pre-COVID-19 vasculitis damage index and revised five factor scores between our and literature GPA+COVID-19
cases.
Literature cases* (n = 11)

Our cases (n = 6)

Total (n = 17)

Revised FFS, median (min-max)

2 (0–2)

2 (0–2)

2 (0–2)

Revised FFS scores, n (%)
0
1
2

3 (27)
2 (18)
6 (55)

1 (17)
1 (17)
4 (66)

4 (22)
3 (17)
10 (56)

VDI, median (min-max)

0 (0–2)

1 (0–6)

0 (0–6)

* Revised FFS and VDI scores were not available for one literature case. All comparisons between our cohort and literature were
statistically insignificant. FFS: Five factor score, VDI: Vasculitis damage index.
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Table 4. Detailed clinical features of granulomatosis polyangiitis patients with COVID-19 disease.
Granulomatosis with polyangiitis related
Patient Age (years), Major organ
no.
sex
involvement

Duration
Treatments
(years)

1

4

66, F

Pulmonary

COVID-19 disease related
Last dose of
Pneumonia
RTX

MTX
MPZ 4 mg

Treatments

Hospitalization

Mortality

No

No

No

No

Yes

2

71, M

Pulmonary
Renal

2

MPZ 4 mg

Yes

Azithromycin
Favipiravir
MPZ
Yes
PEX
LMWH

3

43, M

Pulmonary
Renal

3

AZA 50 mg
MPZ 4 mg

No

Favipiravir

No

No

4

59, M

Neuropathy

4

RTX
AZA
MPZ 4 mg

Yes

Favipiravir
MPZ Pulse
IVIg

Yes

Yes

5

45, F

Renal

1

AZA

Yes

LMWH

Yes

No

6

88, M

Pulmonary

1

CYC

Yes

HCQ

Yes

No

Yes

Remdesivir
DXM 8 mg
CPT
LMWH

Yes

No

4 months

7

21, M

Pulmonary

3

MMF 3 gr
MPZ 24 mg

8

40, M

None

2 months

MTX
MPZ

Yes

None

Yes

No

9

37, F

Pulmonary

15

MPZ Pulse
PEX

No

TCZ

Yes

Yes

Yes

No

NA

No

Azithromycin
10*

77, M

Pulmonary
18
Pachymeningitis

RTX
MPZ 32 mg

1 month

11*

30, F

None

NA

RTX

2.5 months NA

12

35, E

Pulmonary

7

RTX
AZA
MPZ 6 mg

NA

Yes

Azithromycin
Yes
HCQ

No

13

63, M

Renal

7

RTX
MPZ 4 mg

14 days

Yes

None

Yes

No

14

77, F

None

3

RTX
MPZ 4 mg

1 month

Yes

NA

Yes

No

15*

61, F

Pulmonary
Renal

1

RTX
CYC
MPZ 24 mg

5 months

NA

Yes

No

904

Yes

Remdesivir
MPZ 12 mg
CPT
None
Bamlanivimab

None
DXM
LMWH
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Table 4. (Continued.)

Yes

Azithromycin
HCQ
Yes
Lopinavir/
ritonavir

No

16

55, M

Pulmonary
Renal
27
Pachymeningitis

17

80, M

Renal

7

RTX

NA

Yes

MPZ
PEX

Yes

Yes

18

52, F

Pulmonary

33

RTX
MPZ 12 mg

7 days

Yes

Lopinavir/
ritonavir
HCQ

Yes

No

RTX
MPZ 4 mg

5 months

*Cases with COVID-19 reinfection. In COVID-19 specific treatment squares, the top line shows the drugs used for the initial infection,
and the bottom line shows the drugs used for reinfection.
RTX: Rituximab, MTX: Methotrexate, MPZ: Methylprednisolone, PEX: Plasmapheresis, LMWH: Low molecular weight heparin,
AZA: Azathioprine, IVIg: Intravenous immune globulin G, CYC: Cyclophosphamide, HCQ: Hydroxychloroquine sulfate, MMF:
Mycophenolate mofetil, DXM: Dexamethasone, CPT: Convalescent plasma therapy, NA: Nonavailable, TCZ: Tocilizumab.
Table 5. Comparison of demographic, clinical characteristics and treatments between deceased and surviving GPA+COVID-19 cases.
Deceased (n = 4)

Surviving (n = 14)

Total (n = 18)

p value

Median age, years (SD)

61.8 (18.6)

53.8 (19.4)

55.6 (19.0)

0.477

Male, n (%)

3 (75)

8 (57)

11 (61)

0.486

Pulmonary involvement, n (%)

1/3 (3)

9/13 (69)

9/16 (56)

0.304

Renal involvement, n (%)

2/3 (67)

5/12 (42)

7/15 (47)

0.538

Ground glass opacitiesin thorax CT, n (%)

3/4 (75)

10/11 (91)

13/15 (87)

0.476

Prednisonedosage, mg/day, median (min-max)

4 (-)

6.2 (4-40)

5 (15)

0.364

Rituximab, n (%)

2/3 (67)

8/13 (62)

10 (63)

0.696

GPA: Granulomatosis with polyangiitis, CT: Computed tomography.

pulmonary involvement in thoracic CT due to GPA in
3, renal involvement due to GPA in 5 (4 necrotizing
glomerulonephritis). In these COVID-19 induced GPA
patients, the most common COVID-19 symptom was
fever with 66%. In comparison to GPA+COVID-19
patients, COVID-19 induced GPA patients had a higher
cough, dyspnea and a lower fatigue and arthralgia/myalgia
incidence. Of these patients, 83% had ground-glass
opacities on thorax CT, and 66% had RT-PCR positivity.
Oxygen support was needed in 2 patients and mortality
was observed in 1 patient.
4. Discussion
The frequency and mortality of COVID-19 were 7.4% and
33% in our GPA cohort, respectively. Among the literature
cases, the most common symptoms of GPA+COVID-19
cases were fever, cough, arthralgia/myalgia, and

malaise. The most frequent treatments for GPA before
the COVID-19 infection were prednisone (72%) and
rituximab (56%). Three patients receiving rituximab also
had COVID-19 reinfection. Mortality due to COVID-19
was observed in 4 (22%) of 18 GPA+COVID-19 patients.
The most common symptoms of COVID-19 induced
GPA were dyspnea in addition to those common in
GPA+COVID-19, such as fever and cough.
In our current literature review, there was no study on
the incidence of COVID-19 in GPA patients. AAVs were
only 2% in the European League Against Rheumatism
(EULAR) COVID-19 database with 4373 cases registered2.
In total, 7.4% of GPA patients in our cohort had COVID-19
disease and the mortality rate was 33%. According to
WHO COVID-19 dashboard, global mortality rates of
COVID-19 was 2.13% at the same time as our study3.3

EULAR COVID-19 Database (2021). European paediatric and adult database [Online]. Website https://www.eular.org/myUploadData/files/eular_
covid_19_registry_report_20210201.pdf [accessed 01 July 2021].
2

3

World Health Organization (2021). WHO Coronavirus (COVID-19) Dashboard [Online]. Website https://covid19.who.int/info [accessed 01 July 2021].
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Table 6. Demographic, clinical and laboratory characteristics of COVID-19 induced GPA cases.
Total, (n = 6)
Median age, years (min-max)

42 (25–60)

Male, n (%)

3 (50)

Symptom, n (%)
Fever

4 (66)

Cough

4 (66)

Dyspnea

3 (50)

Hemoptysis

2 (33)

Fatigue

2 (33)

Chest pain

1 (17)

Arthralgia/Myalgia

1 (17)

Anorexia

1 (17)

Rhinitis

1 (17)

RT-PCR positivity, n (%)

4 (66)

Lymphopenia, n (%)

1 (17)

Ground glass opacities in thorax CT, n (%)

5 (83)

C-reactive protein (>5 mg/L), n (%)

3 (50)

Need for O2 support, n (%)

2 (33)

Mortality, n (%)

1 (17)

GPA: Granulomatosis with polyangiitis, RT-PCR: Reverse transcriptase–polymerase chain reaction, CT: Computed tomography.

We observed a higher mortality rate in GPA patients with
COVID-19 in our study. According to the COVID-19
Global Rheumatology Alliance (GRA) Physician-Reported
Registry, COVID-19-related mortality among patients with
rheumatic disease is associated with advanced age, male
sex, certain comorbidities and disease-specific factors like
disease activity and certain medications [13]. The course of
the COVID-19, especially in patients receiving rituximab,
could be severe [13, 41, 42]. In a multicenter study
including diverse rheumatological diseases, mortality was
observed in 7 of 17 AAV patients with COVID-19, and
it was reported that rituximab was used in 4 of these 7
patients [43]. Rituximab is a biological agent that binds to
CD20 on the surface of B lymphocyte cells and inhibits
antibody development [44]. These potential deteriorating
effects of rituximab on COVID-19 disease course could
be likely due to these alterations in the humoral immune
system. Although rituximab use was similar between
deceased and surviving GPA+COVID-19 patients in
our study, it was shown that rituximab therapy was used
in 60% of 18 patients and in all patients who developed
COVID-19 reinfection. Therefore, these data suggest that
rituximab therapy may be a negative factor for COVID-19
disease prognosis once again. Apart from rituximab, it has
also been reported in various case reports that the use of
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glucocorticoids (≥10 mg/day prednisone) increases the
hospitalization rate and mortality risk due to COVID-19
disease [13, 27, 45, 46]. In our study, comparison of the
GPA+COVID-19 patients with and without prednisone use
at any dose, oxygen requirement, length of hospitalization,
ICU admission rate, and mortality was similar. According
to the COVID-19 GRA physician-reported registry data,
other factors associated with COVID-19-related mortality
in patients with rheumatic disease were disease activity
and organ damage [13]. Although there was no statistical
difference in terms of VDI and revised FFS scores between
the deceased GPA+COVID-19 patients and survivors,
these scores were higher in GPA+COVID-19 deceased
patients in our study.
COVID-19 induced GPA has been reported in 6
patients with respect to literature data. The frequency of
fever and cough was similar between GPA+COVID-19
and COVID-19 induced GPA patients. But, in comparison
to GPA+COVID-19 patients, COVID-19 induced GPA
patients had higher frequency of dyspnea and lower
frequency of fatigue and arthralgia/myalgia. According to
these findings, in patients with constitutional symptoms
predominantly other than fever, COVID-19 could be
considered more prioritized in the differential diagnosis
of GPA. In a patient presenting with similar symptoms,
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if pulmonary complaints such as cough and dyspnea are
more predominant from fatigue and arthralgia/myalgia,
which are non-specific findings, GPA should always be
considered, except for COVID-19 disease. In the light of
all this limited and speculative data, COVID-19 disease
should be kept in mind in the differential diagnosis of GPA
and vice versa.
This has been the first study about the incidence of
COVID-19 in GPA patients in single-center. However,
there were some limitations. Most importantly, it has been
a retrospective study and the number of patients was little.
In addition, the literature case reports were from different
centers and the lack of clinical and laboratory data of them
(especially the presence of hypogammaglobulinemia for
patients receiving rituximab) were other limitations of
this study. RT-PCR is repeated 2–3 times every other day
for our patients with RT-PCR negativity but with a high
suspicion of COVID-19, but there was no clear data on
what was done in these situations in the literature cases.
Last, the status of GPA at the COVID-19 disease, and also

the information on whether mortality due to COVID-19
disease or post-COVID vasculitis activation is not clear.
In conclusion, the frequency of COVID-19 in our GPA
cohort was 7.4% and the mortality rate due to COVID-19
was higher. In patients followed up with GPA, rituximab
treatment may be precarious for both COVID-19 disease
and reinfection. Finally, a patient presenting with GPA
findings should also be examined for COVID-19 disease.
To obtain more accurate results about COVID-19 disease
in GPA patients, more comprehensive studies with more
patients are needed.
Conflict of interest
The authors declare no conflicts of interest that may have
influenced either the conduct or the presentation of the
research.
Informed consent
The study protocol was approved by the Ethics Committee
of Ankara City Hospital (E2-21-173).

References
1.

2.

3.

4.

Wiersinga WJ, Rhodes A, Cheng AC, Peacock SJ, Prescott HC.
Pathophysiology, Transmission, Diagnosis, and Treatment
of Coronavirus Disease 2019 (COVID-19): A Review. The
Journal of The American Medical Association. 2020; 324 (8):
782-793. doi: 10.1001/jama.2020.12839
Wu Z, McGoogan JM. Characteristics of and Important
Lessons From the Coronavirus Disease 2019 (COVID-19)
Outbreak in China: Summary of a Report of 72314 Cases From
the Chinese Center for Disease Control and Prevention. The
Journal of The American Medical Association. 2020; 323 (13):
1239-1242. doi: 10.1001/jama.2020.2648
Zheng Z, Peng F, Xu B, Zhao J, Liu H et al. Risk factors of critical
& mortal COVID-19 cases: A systematic literature review and
meta-analysis. Journal of Infection. 2020; 81 (2): e16-e25. doi:
10.1016/j.jinf.2020.04.021
Zhou F, Yu T, Du R, Fan G, Liu Y et al. Clinical course and
risk factors for mortality of adult inpatients with COVID-19 in
Wuhan, China: a retrospective cohort study. Lancet. 2020; 395
(10229): 1054-1062. doi: 10.1016/S0140-6736(20)30566-3

5.

Jagiello P, Gross WL, Epplen JT. Complex genetics of Wegener
granulomatosis. Autoimmun Reviews. 2005; 4 (1): 42-47. doi:
10.1016/j.autrev.2004.06.003

6.

Lind E, Jameson A, Kurban E. Fulminant granulomatosis with
polyangiitis presenting with diffuse alveolar haemorrhage
following COVID-19. BMJ Case Rep. 2021; 14 (6): e242628.
doi: 10.1136/bcr-2021-242628

7.

Luqmani RA, Bacon PA, Beaman M, Scott DG, Emery P
et al. Classical versus non-renal Wegener’s granulomatosis.
Quarterly Journal of Medicine. 1994; 87 (3): 161-167.

8.

Schilder AM. Wegener’s Granulomatosis vasculitis and
granuloma. Autoimmun Reviews. 2010; 9 (7): 483-487. doi:
10.1016/j.autrev.2010.02.006

9.

Akiyama S, Hamdeh S, Micic D, Sakuraba A. Response to:
‘Correspondence on ‘Prevalence and clinical outcomes of
COVID-19 in patients with autoimmune diseases: a systematic
review and meta-analysis’’ by Yang et al. Annals of the Rheumatic
Diseases. 2021. doi: 10.1136/annrheumdis-2021-219855

10.

Ozdemir B, Erden A, Guven SC, Armagan B, Apaydin H et al.
COVID-19 and eosinophilic granulomatosis with polyangiitis
or COVID-19 mimicking eosinophilic granulomatosis with
polyangiitis? Rheumatology International. 2021; 41 (8): 15151521. doi: 10.1007/s00296-021-04896-2

11.

Pablos JL, Abasolo L, Alvaro-Gracia JM, Blanco FJ, Blanco
R et al. Prevalence of hospital PCR-confirmed COVID-19
cases in patients with chronic inflammatory and autoimmune
rheumatic diseases. Annals of the Rheumatic Diseases. 2020;
79 (9): 1170-1173. doi: 10.1136/annrheumdis-2020-217763

12.

Pablos JL, Galindo M, Carmona L, Lledo A, Retuerto M et al.
Clinical outcomes of hospitalised patients with COVID-19
and chronic inflammatory and autoimmune rheumatic
diseases: a multicentric matched cohort study. Annals of the
Rheumatic Diseases. 2020; 79 (12): 1544-1549. doi: 10.1136/
annrheumdis-2020-218296

13.

Strangfeld A, Schafer M, Gianfrancesco MA, Lawson-Tovey S,
Liew JW et al. Factors associated with COVID-19-related death
in people with rheumatic diseases: results from the COVID-19
Global Rheumatology Alliance physician-reported registry.
Annals of the Rheumatic Diseases. 2021; 80 (7): 930-942. doi:
10.1136/annrheumdis-2020-219498

907

ARMAĞAN et al. / Turk J Med Sci
14.

de Wit E, van Doremalen N, Falzarano D, Munster VJ. SARS
and MERS: recent insights into emerging coronaviruses.
Nat Rev Microbiol. 2016; 14 (8): 523-534. doi: 10.1038/
nrmicro.2016.81

15.

Haberman R, Axelrad J, Chen A, Castillo R, Yan D et al.
Covid-19 in Immune-Mediated Inflammatory Diseases - Case
Series from New York. New England Journal of Medicine. 2020;
383 (1): 85-88. doi:10.1056/NEJMc2009567

16.

Monti S, Balduzzi S, Delvino P, Bellis E, Quadrelli
VS, Montecucco C. Clinical course of COVID-19 in
a series of patients with chronic arthritis treated with
immunosuppressive targeted therapies. Annals of the
Rheumatic Diseases. 2020; 79 (5): 667-668. doi: 10.1136/
annrheumdis-2020-217424

17.

Guo L, Ren L, Yang S, Xiao M, Chang et al. Profiling Early
Humoral Response to Diagnose Novel Coronavirus Disease
(COVID-19). Clinical Infectious Diseases. 2020; 71 (15): 778785. doi: 10.1093/cid/ciaa310

18.

Russell B, Moss C, George G, Santaolalla A, Cope A et al.
Associations between immune-suppressive and stimulating
drugs and novel COVID-19-a systematic review of current
evidence. Ecancermedicalscience. 2020; 14: 1022. doi: 10.3332/
ecancer.2020.1022

19.

Selvaraj V, Moustafa A, Dapaah-Afriyie K, Birkenbach MP.
COVID-19-induced granulomatosis with polyangiitis. BMJ
Case Rep. 2021; 14 (3): e242142. doi: 10.1136/bcr-2021-242142

20.

Izci Duran T, Turkmen E, Dilek M, Sayarlioglu H, Arik N.
ANCA-associated vasculitis after COVID-19. Rheumatology
International. 2021; 41 (8): 1523-1529. doi: 10.1007/s00296021-04914-3

21.

22.

23.

24.

908

Leavitt RY, Fauci AS, Bloch DA, Michel BA, Hunder GG et
al. The American College of Rheumatology 1990 criteria
for the classification of Wegener’s granulomatosis. Arthritis
Rheumatology. 1990; 33 (8): 1101-1107. doi: 10.1002/
art.1780330807
Guilpain P, Le Bihan C, Foulongne V, Taourel P, Pansu N
et al. Rituximab for granulomatosis with polyangiitis in
the pandemic of covid-19: lessons from a case with severe
pneumonia. Annals of the Rheumatic Diseases. 2021; 80 (1):
e10. doi:10.1136/annrheumdis-2020-217549
Hakroush S, Franz J, Larsen J, Korsten P, Winkler MS,
Tampe B. Repeated false-negative tests delayed diagnosis of
COVID-19 in a case with granulomatosis with polyangiitis
under maintenance therapy with rituximab and concomitant
influenza pneumonia. Annals of the Rheumatic Diseases. 2020.
doi: 10.1136/annrheumdis-2020-218491
Daniel P, Raad M, Waked R, Choucair J, Riachy M, Haddad
F. COVID-19 in a Patient Treated for Granulomatosis with
Polyangiitis: Persistent Viral Shedding with No Cytokine
Storm. European Journal of Case Reports in Internal Medicine.
2020; 7 (10): 001922. doi: 10.12890/2020_001922

25.

Gulati K, Prendecki M, Clarke C, Willicombe M,
McAdoo S. COVID-19 Reinfection in a Patient Receiving
Immunosuppressive
Treatment
for
Antineutrophil
Cytoplasmic Antibody-Associated Vasculitis. Arthritis
Rheumatology. 2021; 73 (6): 1091-1092. doi: 10.1002/art.41671

26.

Fallet B, Kyburz D, Walker UA. Mild Course of COVID-19
and Spontaneous Virus Clearance in a Patient With Depleted
Peripheral Blood B Cells Due to Rituximab Treatment.
Arthritis Rheumatology. 2020; 72 (9): 1581-1582. doi: 10.1002/
art.41380

27.

Leipe J, Wilke EL, Ebert MP, Teufel A, Reindl W. Long,
relapsing, and atypical symptomatic course of COVID-19
in a B-cell-depleted patient after rituximab. Semin Arthritis
Rheumatology. 2020; 50 (5): 1087-1088. doi: 10.1016/j.
semarthrit.2020.06.013

28.

Friedman MA, Winthrop KL. Second COVID-19 infection in
a patient with granulomatosis with polyangiitis on rituximab.
Annals of the Rheumatic Diseases. 2021. doi: 10.1136/
annrheumdis-2021-220088

29.

Shenavandeh S, Sefidbakht S, Iranpour P, Teimouri A,
Hooshmandi S et al. COVID-19 and granulomatosis with
polyangiitis (GPA): a diagnostic challenge. Rheumatology
(Oxford). 2020; 59 (8): 2170-2171. doi: 10.1093/rheumatology/
keaa326

30.

Ince B, Bektas M, Koca N, Agargun BF, Zarali S et al. A single
center survey study of systemic vasculitis and COVID-19
during the first months of pandemic. Turkish Journal of
Medical Sciences. 2021; 51 (5): 2243-2247. doi: 10.3906/sag2010-267

31.

Rodriguez-Pla A, Vikram HR, Khalid V, Wesselius LJ.
COVID-19 pneumonia in a patient with granulomatosis with
polyangiitis on rituximab: case-based review. Rheumatology
International. 2021; 41 (8) :1509-1514. doi: 10.1007/s00296021-04905-4

32.

Masiak A, Nowakowski S, Zdrojewski Z. SARS-CoV-2 infection
associated with active granulomatosis with polyangiitis. Polish
Archives of Internal Medicine. 2021; 131 (6): 563-565. doi:
10.20452/pamw.15993

33.

Bressler MY, Pathak N, Cervellione K, Bagheri F, Epstein E et
al. New Onset Granulomatosis with Polyangiitis Associated
with COVID-19. Case Reports in Dermatological Medicine.
2021; 2021: 8877292. doi: 10.1155/2021/8877292

34.

Hussein A, Al Khalil K, Bawazir YM. Anti-Neutrophilic
Cytoplasmic Antibody (ANCA) Vasculitis Presented as
Pulmonary Hemorrhage in a Positive COVID-19 Patient: A
Case Report. The Cureus Journal of Medical Sciences. 2020; 12
(8): e9643. doi: 10.7759/cureus.9643

35.

Moeinzadeh F, Dezfouli M, Naimi A, Shahidi S, Moradi H.
Newly Diagnosed Glomerulonephritis During COVID-19
Infection Undergoing Immunosuppression Therapy, a Case
Report. The Iranian Journal of Kidney Diseases. 2020; 14 (3):
239-242.

ARMAĞAN et al. / Turk J Med Sci
36.

Uppal NN, Kello N, Shah HH, Khanin Y, De Oleo IR et al. De
Novo ANCA-Associated Vasculitis With Glomerulonephritis
in COVID-19. Kidney International Reports. 2020; 5 (11):
2079-2083. doi: 10.1016/j.ekir.2020.08.012

37.

Exley AR, Bacon PA, Luqmani RA, Kitas GD, Gordon C et al.
Development and initial validation of the Vasculitis Damage
Index for the standardized clinical assessment of damage in the
systemic vasculitides. Arthritis Rheumatology. 1997; 40 (2):
371-380. doi: 10.1002/art.1780400222

38.

Guillevin L, Pagnoux C, Seror R, Mahr A, Mouthon
L et al. The Five-Factor Score revisited: assessment of
prognoses of systemic necrotizing vasculitides based
on the French Vasculitis Study Group (FVSG) cohort.
Medicine (Baltimore). 2011; 90 (1): 19-27. doi: 10/1097/
MD.0b013e318205a4c6

39.

Mukhtyar C, Lee R, Brown D, Carruthers D, Dasgupta B et
al. Modification and validation of the Birmingham Vasculitis
Activity Score (version 3). Annals of the Rheumatic Diseases.
2009; 68 (12): 1827-1832. doi: 10.1136/ard.2008.101279

40.

Yumura W, Kobayashi S, Suka M, Hayashi T, Ito S et al.
Assessment of the Birmingham vasculitis activity score in
patients with MPO-ANCA-associated vasculitis: sub-analysis
from a study by the Japanese Study Group for MPO-ANCAassociated vasculitis. Modern Rheumatology. 2014; 24 (2): 304309. doi: 10.3109/14297595.2013.854075

41.

Loarce-Martos J, Garcia-Fernandez A, Lopez-Gutierrez F,
Garcia-Garcia V, Calvo-Sanz L et al. High rates of severe
disease and death due to SARS-CoV-2 infection in rheumatic
disease patients treated with rituximab: a descriptive study.
Rheumatology International. 2020; 40 (12): 2015-2021. doi:
10.1007/s00296-020-04699-x

42.

Yasuda H, Tsukune Y, Watanabe N, Sugimoto K, Uchimura
A et al. Persistent COVID-19 Pneumonia and Failure to
Develop Anti-SARS-CoV-2 Antibodies During Rituximab
Maintenance Therapy for Follicular Lymphoma. Clinical
Lymphoma, Myeloma &Leukemia. 2020; 20 (11): 774-776. doi:
10.1016/j.clml.2020.08.017

43.

FAI2R /SFR/SNFMI/SOFREMIP/CRI/IMIDIATE consortium
and contributors. Severity of COVID-19 and survival in
patients with rheumatic and inflammatory diseases: data from
the French RMD COVID-19 cohort of 694 patients. Annals of
the Rheumatic Diseases. 2020; 80 (4): 527-538. doi: 10.1136/
annrheumdis-2020-218310

44.

Mehta P, Porter JC, Chambers RC, Isenberg DA, Reddy V.
B-cell depletion with rituximab in the COVID-19 pandemic:
where do we stand? Lancet Rheumatology. 2020; 2 (10):
e589-e590. doi: 10.1016/S2665-9913(20)30270

45.

Nuno L, Novella Navarro M, Bonilla G, Franco-Gomez K et al.
Clinical course, severity and mortality in a cohort of patients
with COVID-19 with rheumatic diseases. Annals of the
Rheumatic Diseases. 2020; 79 (12): 1659-1661. doi: 10.1136/
annrheumdis-2020-218054

46.

Schulze-Koops H, Krueger K, Vallbracht I, Hasseli R,
Skapenko A. Increased risk for severe COVID-19 in patients
with inflammatory rheumatic diseases treated with rituximab.
Annals of the Rheumatic Diseases. 2021; 80 (5): e67. doi:
10.1136/annrheumdis-2020-218075

909

